drugset
Drugs / emtricitabine/tenofovir disoproxil fumarate
last change Oct 2016 re-read 9 days ago

emtricitabine/tenofovir disoproxil fumarate

also known as FTC/TDF

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 3 NCT00116805 Background Jun 2005 → May 2007 chronic hepatitis B virus infection Gilead Sciences Completed Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2016-10-24 Gilead Sciences Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens gilead.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as emtricitabine/tenofovir disoproxil fumarate “Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.” NCT00116805 ↗
Known as FTC/TDF “Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.” NCT00116805 ↗
Route Oral “200/300 mg fixed-dose combination (FDC) tablet administered orally once daily” NCT00116805 ↗